Results of a 2-Stage, Phase 3 Pivotal Trial, EDEMA3®: A Study of Subcutaneous DX-88 (Ecallantide), a Plasma Kallikrein Inhibitor, in Patients with Hereditary Angioedema (HAE)

2008 ◽  
Vol 121 (2) ◽  
pp. S231-S231 ◽  
Author(s):  
R LEVY ◽  
D MCNEIL ◽  
H LI ◽  
F HSU ◽  
P HORN ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Plasma Kallikrein ◽  
Pivotal Trial ◽  
Phase 3 ◽  
Kallikrein Inhibitor

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

2021 ◽  
Vol 64 (17) ◽  
pp. 12453-12468
Author(s):  
Pravin L Kotian ◽  
Minwan Wu ◽  
Satish Vadlakonda ◽  
Venkat Chintareddy ◽  
Pengcheng Lu ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Plasma Kallikrein ◽  
Kallikrein Inhibitor

scholarly journals Preclinical Characterization of BCX7353, an Oral Plasma Kallikrein Inhibitor, for the Treatment of Hereditary Angioedema (HAE)

2017 ◽  
Vol 139 (2) ◽  
pp. AB230 ◽  
Author(s):  
Xilin Chen ◽  
Pravin Kotian ◽  
Ramanda Wilson ◽  
Cynthia D. Parker ◽  
Y.S. Babu
Keyword(s):  
Hereditary Angioedema ◽  
Plasma Kallikrein ◽  
Kallikrein Inhibitor

scholarly journals Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study

Allergy ◽  
2018 ◽  
Vol 73 (9) ◽  
pp. 1871-1880 ◽  
Author(s):  
M. A. Riedl ◽  
E. Aygören-Pürsün ◽  
J. Baker ◽  
H. Farkas ◽  
J. Anderson ◽  
...  
Keyword(s):  
Hereditary Angioedema ◽  
Phase 3 ◽  
Kallikrein Inhibitor
Sign in / Sign up

Export Citation Format

Share Document